Developed using MIT's open-source ChemProp package, the foundation model was trained on calculated molecular descriptors from the National Institutes of Health's PubChem database rather than scientific literature. It evaluates roughly 1,600 established descriptors, including molecular weight and oxygen counts, to forecast characteristics ranging from solubility to protein reactivity. The publicly available tool has already demonstrated competitive success by projecting the properties of unsynthesized molecules. At least one pharmaceutical company has integrated the system into its mandatory protocol for molecular modeling workflows.
Key points
CheMeleon allows researchers to predict molecular behaviors like viscosity and bioactivit…: CheMeleon allows researchers to predict molecular behaviors like viscosity and bioactivity despite severe limitations in available experimental data.
The system is built on MIT's ChemProp package and is publicly accessible for users to dow…: The system is built on MIT's ChemProp package and is publicly accessible for users to download and fine-tune.
Commercial interest emerged before formal publication, prompting at least one pharmaceuti…: Commercial interest emerged before formal publication, prompting at least one pharmaceutical firm to mandate the tool as an initial modeling step.
Sources checked by our analysis pipeline: 1
Discovering new molecules for specific uses is a major driver of progress in a wide variety of industries, whether it’s pharmaceutical companies looking for new drugs, or electronics or energy companies seeking new materials with particular properties. But it’s also largely a trial-and-error process, because there is not yet any way to perfectly predict how a given chemical compound will behave in terms of the myriad different properties and responses materials can exhibit.
Recent progress has been made on using artificial intelligence and machine learning to supplement or speed up laborious calculations based on physical principles that can at least provide some initial guidance on which compounds might be worth synthesizing and testing. Now, a new method developed at MIT shows that when there are few data on some technologically relevant property, such as ligand affinities for a recently discovered cellular target for a potential drug, this approach can outperform other existing methods for winnowing down the field of possible molecules that might be worth looking at.
The findings were reported in the Sept. 14 issue of the Journal of…
State-level voter restrictions on energy- and water-intensive data centres have triggered sharp sell-offs in semiconductor and artificial intelligence infrastructure shares. These sudden regulatory hurdles have reignited broader market fears over circular financing, questionable revenues, and unsustainable debt structures across the sector. Heavily leveraged firms now face prolonged development timelines and surging capital costs to secure alternate power and operational sites.
OpenAI has secured $11 billion in new funding, according to a report from Bloomberg News. The investment values the artificial intelligence company at $1.25 trillion.
The artificial intelligence company has completed the initial portion of a massive investment round reported on Friday. This injection of fresh capital marks a major financial milestone as the firm continues advancing its broader financing efforts.